echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 3SBio's new anti-pruritic drug TRK-820 is declared for listing

    3SBio's new anti-pruritic drug TRK-820 is declared for listing

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    On December 21, 3SBio and its partner company, Toray Co.


    Hemodialysis patients are often accompanied by complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperparathyroidism, pruritus, etc.


    Nafuraphine hydrochloride is a selective opioid κ receptor agonist independently developed by Toray Co.


    In 2009, Nafuraphine Hydrochloride Soft Capsules was approved in Japan to improve pruritus in hemodialysis patients (only if the current treatment effect is not satisfactory), and subsequently, chronic liver disease patients and refractory pruritus in peritoneal dialysis patients Symptoms and other indications have also been approved one after another


    The NDA in China is based on the results of a randomized, double-blind, placebo-controlled, multi-center bridging clinical study completed in China


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.